Denosumab for Type 1 Diabetes

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

October 11, 2027

Study Completion Date

October 11, 2027

Conditions
Type 1 Diabetes
Interventions
DRUG

Denosumab

Denosumab is a sterile, preservative-free, clear, colorless to pale yellow solution. Each 1 mL single-dose prefilled syringe of denosumab contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2.

OTHER

Placebo

Placebo is 1 mL of normal saline drawn up in a commercially available syringe.

Trial Locations (3)

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

46202

RECRUITING

Indiana University, Indianapolis

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
lead

City of Hope Medical Center

OTHER